

## STAVROS V. KONSTANTINIDES, MD, PhD, FESC, FRCP(Glasg)

<b>CV Summary</b>	<p>Stavros Konstantinides was appointed as full professor of cardiology at the Democritus University of Thrace, Greece, in 2009. He is also professor for multicenter academic clinical trials at the multidisciplinary Center for Thrombosis and Hemostasis (CTH), Johannes Gutenberg University of Mainz, Germany. The CTH, supported by the federal German government, is dedicated to integrated patient-oriented research and care. He graduated from the Aristotle University of Thessalonica in 1987, and completed his clinical training in cardiology at the University of Freiburg, Germany, obtaining his doctoral degree in 1993. He has worked as clinical and interventional cardiologist since 1997. Between 1998 and 2009, he was assistant and subsequently associate professor of medicine at the Universities of Freiburg and Goettingen, Germany. From January 1999 through April 2000 he worked as Research Associate at the Department of Vascular Biology, the Scripps Research Institute, La Jolla, CA. For 35 years, his research has been focusing on the cardiovascular system with particular emphasis on thrombotic diseases of the veins and the pulmonary vasculature. He has designed and coordinated several high-impact national and international multicenter trials. His research is funded by national and European peer-reviewed granting agencies as well as industrial partners. He is leading member of national, European, and global (INVENT-VTE) committees, task forces for international guidelines (including those of the European Society of Cardiology [ESC], 2008, 2014, 2019), and of networks focusing on the pulmonary circulation and right ventricular function (e.g., Chair of the European EXPERT-PE network within the Acute Cardiovascular Care Association of the ESC, Board member of the US PERT Consortium™).</p>
<b>Career Path</b>	<p><b>2009–today:</b> Appointed Professor of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece</p> <p><b>2012–today:</b> Appointed Professor for Clinical Trials, CTH, University Medical Center of the Johannes Gutenberg University, Mainz, Germany</p> <p><b>2000–2009:</b> Associate Professor of Medicine and managing senior physician, Dept of Cardiology and Pulmonary Medicine, University Medical Center Göttingen, Germany</p> <p><b>1999–2000:</b> Research Associate with David J. Loskutoff, Ph.D., Department of Vascular Biology, The Scripps Research Institute, La Jolla, California, USA</p> <p><b>1998–1999:</b> Assistant Professor of Medicine, Department of Cardiology and Pulmonary Medicine, University Medical Center Göttingen</p> <p><b>1998:</b> Board Certification in Cardiology</p> <p><b>1998:</b> Habilitation in Internal Medicine, University of Freiburg</p> <p><b>1997:</b> Board Certification in Internal Medicine</p> <p><b>1991–1993:</b> Doctoral thesis at the University of Freiburg: “Surgical Closure vs. Medical Treatment of Atrial Septal Defect in Adults: Long-Term Follow-up”; grade: <i>magna cum laude</i>; published in the <i>New England Journal of Medicine</i> 1995</p> <p><b>1990–1997:</b> Clinical training in Internal Medicine and Cardiology, Department of Cardiology, University Clinic Freiburg, Germany</p> <p><b>1988–1990:</b> Military service (Greece)</p> <p><b>1982–1987:</b> Medical School, Aristotle University of Thessalonica, Greece</p>
<b>Honors and Awards</b>	<p><b>2025:</b> Klaus Breddin International Honorary Award for Education in Vascular Medicine, Vascular Access Society, Germany</p> <p><b>2019:</b> Visiting Professor, University of Belgrade, Serbia</p> <p><b>2017:</b> Theodor Naegeli Prize for Thrombosis Research, Switzerland</p> <p><b>2017:</b> Jaap de Graeff Medal, Leiden University Medical Center, The Netherlands</p> <p><b>2015:</b> Honorary Fellow, Royal College of Physicians &amp; Surgeons of Glasgow, UK</p> <p><b>2015:</b> Honorary Fellow, Romanian Society of Cardiology</p> <p><b>2004:</b> Novartis Foundation Prize</p> <p><b>2001:</b> William Harvey Prize, International Society on Thrombosis &amp; Haemostasis</p>

**Publications (selection)****Scopus:****number of publications**  
**569;****number of citations,**  
**46,407;****h-index, 87****Google Scholar:****number of publications**  
**811;****number of citations,**  
**89,825;****h-index, 101**

- Farmakis IT, Christodoulou KC, Hobohm L, **Konstantinides SV**. Lipid lowering for prevention of venous thromboembolism: a network meta-analysis. *Eur Heart J* 2024. doi: 10.1093/eurheartj/ehae361.
- Mohr K; Keeling B, Kaier K, [...], **Konstantinides SV**, Valerio L, Secemsky EA. Modelling costs of interventional pulmonary embolism treatment: implications of US trends for a European healthcare system. *Eur Heart J Acute Cardiovasc Care* 2024. doi: 10.1093/ehjacc/zuae019.
- Mohr K, Mildenberger P, Neusius T, [...], Konstantinides SV, Binder H, Valerio L. Estimated annual healthcare costs after acute pulmonary embolism: Results from a prospective multicentre cohort study. *Eur Heart J Qual Care Clin Outcomes* 2024. DOI: 10.1093/ehjqcco/qcae050.
- Farmakis IT, Valerio L, Barco S, [...], **Konstantinides SV**, Held M, Dumitrescu D. Cardiopulmonary exercise testing during follow-up after acute pulmonary embolism. *Eur Respir J* 2023. doi: 10.1183/13993003.00059-2023.
- Barco S, Mavromanoliki AC, Kreitner KF, [...], **Konstantinides SV**. Preexisting chronic thromboembolic pulmonary hypertension in acute pulmonary embolism. *Chest* 2023. doi: 10.1016/j.chest.2022.11.045.
- Barco S, Voci D, Held U, [...], **Konstantinides SV**, [...], Kucher N. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol* 2022. doi: 10.1016/S2352-3026(22)00175-2.
- Valerio V, Mavromanoliki AC, [...], **Konstantinides SV** (corresp. author); FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. *Eur Heart J* 2022. doi: 10.1093/eurheartj/ehac206.
- Valerio L, Barco S, Jankowski M, [...], **Konstantinides SV**. Quality of life 3 and 12 months following acute pulmonary embolism: Analysis from a prospective multicenter cohort study. *Chest* 2021. doi: 10.1016/j.chest.2021.01.071.
- Klok FA, Toenges G, [...], **Konstantinides SV**. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre trial. *Lancet Haematol* 2021;8(9): e627-e636.
- Barco S, Valerio L, Ageno W, [...], Konstantinides SV. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. *Lancet Respir Med* 2021. doi: 10.1016/S2213-2600(20)30417-3.
- Barco S, Mahmoudpour SH, [...], **Konstantinides SV**. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. *Lancet Respir Med* 2020;8:277-287.
- Barco S, Schmidtmann I, [...], Wild PS, **Konstantinides SV**, Lankeit M; HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. *Eur Heart J* 2020;41:509-518.
- Keller K, Hobohm L, [...], **Konstantinides SV**, Lankeit M. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. *Eur Heart J* 2020;41:522-529.
- Barco S, [...], **Konstantinides SV**, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. *Eur Heart J* 2019;40:902-910.
- **Konstantinides S**, Vicaut E, Danays T, [...], Meyer G. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. *J Am Coll Cardiol* 2017;69(12):1536-1544.
- Meyer G, Vicaut E, [...], **Konstantinides S**. Fibrinolysis for patients with acute intermediate-risk pulmonary embolism. *N Engl J Med* 2014;370: 1402-1411.
- Verhoeven TI, Ragia G, de Boer A, **Konstantinides S**, et al; the EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. *N Engl J Med* 2013;369(24):2304-2312
- **Konstantinides S**, Geibel A, Heusel G, et al. A randomized trial comparing alteplase plus heparin with heparin alone in patients with acute major pulmonary embolism. *N Engl J Med* 2002;347:1143-1150

<b>Leadership in Multicenter Clinical Trials (selection)</b>	<ul style="list-style-type: none"> <li><i>Leading/Coordinating:</i> <b>HI-PEITHO</b> - Randomized trial of ultrasound-facilitated, catheter-directed thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study. NCT04790370 (ongoing)</li> <li><i>Leading/Coordinating:</i> Pulmonary Embolism International Trial (<b>PEITHO)-3</b> - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism. EudraCT 2018-000816-96 (ongoing)</li> <li><i>Leading/Coordinating:</i> <b>ENABLE-Hip</b> - Enhanced Recovery and Abbreviated Length of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty. NCT06611319 (ongoing)</li> <li><i>Leading/Coordinating:</i> <b>PERSEVERE</b> - Large-bore Mechanical Thrombectomy vs Standard of Care for Acute High-risk Pulmonary Embolism. NCT06588634 (ongoing)</li> <li><i>Leading/Coordinating:</i> <b>SIRIUS</b> - A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis. NCT06149520 (ongoing)</li> <li><i>Leading/Coordinating:</i> <b>PERT-DACH</b> - Prospective multicenter registry on Pulmonary Embolism Response Teams activation in Germany-Austria-Switzerland (ongoing)</li> <li><i>Steering committee member:</i> <b>STORM-PE</b> - A Prospective, Multicenter, Randomized Controlled Trial Evaluating Anticoagulation Alone vs Anticoagulation Plus Mechanical Aspiration With the Indigo® Aspiration System for the Treatment of Intermediate High Risk Acute Pulmonary Embolism. NCT05684796 (ongoing)</li> <li><i>Steering committee member:</i> <b>TORPEDO-NL</b> - Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands. NCT06833827 (ongoing)</li> </ul> <hr/> <ul style="list-style-type: none"> <li><i>Leading/Coordinating:</i> HoT-PE - Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban. EudraCT 2013-001657-28 (completed)</li> <li><i>Leading/Coordinating:</i> Pulmonary Embolism International Trial (PEITHO)-2 - A prospective, multicenter, single-arm management study to investigate the safety and efficacy of low molecular weight heparin followed by dabigatran for the treatment of acute intermediate-risk pulmonary embolism. NCT02596555 (completed)</li> <li><i>Leading/Coordinating:</i> Pulmonary Embolism International Trial (PEITHO) - A prospective, randomised, double-blind, placebo-controlled, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and right ventricular dysfunction. NCT00639743 (completed)</li> <li><i>National coordinator:</i> Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy. NCT01076764 (completed)</li> </ul>
<b>Third Party Funding (selection)</b>  <b>Total external research funding obtained 2012-2025:</b> <b>€15 million</b>	<ul style="list-style-type: none"> <li><i>European Commission, HORIZON Europe:</i> "Project 101095698, MORPHEUS: "PROGNOSIS IMPROVEMENT OF UNPROVOKED VENOUS THROMBO-EMBOLISM USING PERSONALIZED ANTICOAGULANT THERAPY" (ongoing)</li> <li><i>European Commission, HORIZON Europe:</i> "Project 101057292, SERENITY: "TOWARDS CANCER PATIENT EMPOWERMENT FOR OPTIMAL USE OF ANTITHROMBOTIC THERAPY AT THE END OF LIFE" (ongoing)</li> <li><i>Deutsche Forschungsgemeinschaft - DFG</i> (German Research Foundation ► federal public funding), Clinical Trials Program (KO1939/3-1): "Enhanced AAA" trial (ongoing)</li> <li><i>Deutsche Forschungsgemeinschaft, (KO1939/3-1):</i> "PEITHO-III" trial (ongoing)</li> <li><i>Boston Scientific, Penumbra Inc., Inari Medical:</i> Institutional support for leading and coordinating the prospective DACH-PERT Registry (Germany-Austria-Switzerland)</li> <li><i>Daiichi-Sankyo:</i> Institutional support of research on the association between lipid-lowering treatment and VTE prevention (ongoing)</li> <li><i>BMBF</i> (German federal ministry of research; 01EO1003 &amp; 01EO1503): Set-up of an academic clinical trials program at University Medical Center Mainz (2012-2020)</li> <li><i>Boehringer Ingelheim:</i> Institutional support of the PEITHO-2 study (2015-2019)</li> <li><i>Bayer AG:</i> Institutional support of the multicenter HoT-PE study (2014-2018)</li> </ul>

<b>Leadership in Scientific Cardio-vascular Societies, Task Forces, Boards</b>	<ul style="list-style-type: none"> <li>• <i>PERT Consortium™</i>, US: Board member (current)</li> <li>• <i>INVENT-VTE</i> - global network of national networks in academic venous thromboembolism research, Canada: Past Chairperson, Board of Directors</li> <li>• <i>CanVECTOR</i> - Canadian Venous Thromboembolism Research Network: External Advisory Board member (current)</li> <li>• <i>European Society of Cardiology</i>, Task Force for the Guidelines on the Management of Pulmonary Embolism: 1) Task Force member, 2008; 2) Task Force Chairperson: 2014, 2019</li> <li>• <i>European Society of Cardiology</i>, Acute Cardiovascular Care Association: 1) Board member (current); 2) Chairperson, EXPERT-PE Study Group on Pulmonary Embolism (current)</li> <li>• <i>European Society of Cardiology</i>, Working Group on Pulmonary Circulation and Right Ventricular Function: Past Chairperson</li> <li>• <i>German Cardiac Society - DGK</i>: 1) Chairperson, Task Force for Guidance on Establishment of Pulmonary Embolism Response Teams, Use of Advanced (catheter) Treatment (2022-2023); 2) Coordinating Investigator, prospective multicenter DGK-endorsed DACH-PERT Registry in Germany-Austria-Switzerland (current)</li> <li>• <i>Hellenic Cardiac Society (Greece)</i>: Chairperson, Multidisciplinary Task Force for Management of Hemorrhagic Complications in Patients on Oral Anticoagulants (2015-2016)</li> </ul>
<b>Cooperation with Scientific Societies, Authorities, Institutions &amp; Experts from Other Disciplines</b>	<ul style="list-style-type: none"> <li>• <i>ERS</i>: European Respiratory Society</li> <li>• <i>British Thoracic Society</i></li> <li>• <i>ISTH</i>: International Society on Thrombosis and Hemostasis</li> <li>• <i>CIRSE</i>: Cardiovascular and Interventional Radiological Society of Europe</li> <li>• <i>The Fleischner Society</i>: international, multidisciplinary medical society for thoracic radiology</li> <li>• <i>German Society of Angiology (Vascular Medicine)</i></li> <li>• <i>INNOVTE</i>: INvestigation Network On Venous Thrombo-Embolism (France)</li> <li>• <i>VAS</i>: Vascular Access Society</li> <li>• <i>SDA Bocconi School of Management</i>, Bocconi University, Milan, Italy: Health and Social Care Management, focus on Health Economics</li> <li>• <i>Wiesbaden Business School</i>, Wiesbaden, Germany: Health economics</li> <li>• <i>Research Foundation Flanders, Belgium</i>: Reviewer of research grant applications</li> <li>• <i>Ministry of Health, France</i>: Reviewer of research grant applications</li> <li>• <i>National Science Center, Poland</i>: Reviewer of research grant applications</li> <li>• <i>Ministry for Research and Technology, Greece</i>: Reviewer of research grant applications</li> </ul>
<b>Invited Lectures, Seminars, Workshops</b>	<ul style="list-style-type: none"> <li>• Over 1,000 lectures by national/regional/local scientific societies, Universities or other academic institutions in &gt; 40 countries, including: <ul style="list-style-type: none"> <li>○ United States, Canada, Colombia, Argentina</li> <li>○ All countries of the European Union</li> <li>○ United Kingdom, Switzerland</li> <li>○ Ukraine, Serbia, Russia, Turkey</li> <li>○ Israel, Jordan, Kuwait, Saudi Arabia, United Arab Emirates, Oman</li> <li>○ Egypt, Tunisia, Morocco, South Africa</li> <li>○ China, Japan; South Korea</li> </ul> </li> </ul>

Updated November 20, 2025, Stavros V. Konstantinides MD